EHang to Report Second Quarter 2023 Unaudited Financial Results on Thursday, August 17, 2023
August 11, 2023 08:25 ET
|
EHang Holdings Limited
GUANGZHOU, China, Aug. 11, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang and Shenzhen Bao’an District Form Strategic Partnership for Urban Air Mobility Operation Center
July 13, 2023 08:32 ET
|
EHang Holdings Limited
GUANGZHOU, China, July 13, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang Announces US$23 Million Private Placement Led by South Korean Strategic Investor Lee Soo Man
July 11, 2023 16:00 ET
|
EHang Holdings Limited
GUANGZHOU, China, July 12, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
June 01, 2023 05:09 ET
|
Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
May 31, 2023 06:00 ET
|
Coave Therapeutics
CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a...
EHang Reports First Quarter 2023 Unaudited Financial Results
May 31, 2023 05:00 ET
|
EHang Holdings Limited
- Total Revenues Up 41.6% Quarter-over-Quarter- Continued High Quarterly Gross Margin of 60%+- EH216-S Type Certification’s Compliance Tests in Final Phase Completed More Than 90%- Notable Growth of...
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction
May 17, 2023 07:00 ET
|
Sania Therapeutics
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction Sania emerges from stealth mode and presents key proof-of-concept data at ASGCT 2023 ...
Coave Therapeutics to Participate in Upcoming Conferences
May 17, 2023 03:00 ET
|
Coave Therapeutics
Paris, France, May 17, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases,...
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
May 16, 2023 06:00 ET
|
Locanabio, Inc.
LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...
EHang Files Annual Report on Form 20-F for Fiscal Year 2022
April 27, 2023 17:40 ET
|
EHang Holdings Limited
GUANGZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform...